TY - JOUR
T1 - Standards, Options et Recommandations pour le traitement périopératoire des patients atteints d'un cancer bronchique non à petites cellules résécable d'emblée, opérables (mise à jour), rapport abrégé
AU - Besse, Benjamin
AU - Depierre, Alain
AU - Guillo, Sylvie
AU - Séblain-El Guerche, Clotilde
AU - Douillard, Jean Yves
AU - Giniès, Annie
AU - Hennequin, Christophe
AU - Le Péchoux, Cécile
AU - Milleron, Bernard
AU - Moro-Sibilot, Denis
AU - Mouillefarine, Pierre
AU - Quoix, Élisabeth
AU - Régnard, Jean François
AU - Riquet, Marc
AU - Vaylet, Fabien
AU - Zalcman, Gérard
N1 - Funding Information:
cancer, operable has been initiated by the French National Federation of Cancer Centres (FNCLCC). This work was performed in collabora tion with the French Intergroup for Thoracic Oncology (IFCT), the French-speaking Language Society of Pneumology (SPLF), specialists from university or general hospitals and private clinics, and with the French National Cancer Institute. It is based on the methodology deve loped and used in the “Standards, Options and Recommendations” programme. This article presents a short version of the updated 2007 recommendations.
PY - 2007/11/1
Y1 - 2007/11/1
N2 - An update of the Sor Clinical Practice Guidelines (CPG) for the perioperative treatment of operable patients with resecable non-small cell lung cancer, operable has been initiated by the French National Federation of Cancer Centres (FNCLCC). This work was performed in collaboration with the French Intergroup for Thoracic Oncology (IFCT), the French-speaking Language Society of Pneumology (SPLF), specialists from university or general hospitals and private clinics, and with the French National Cancer Institute. It is based on the methodology developed and used in the "Standards, Options and Recommendations" programme. This article presents a short version of the updated 2007 recommendations. The guideline development process is based on literature review and critical appraisal by amultidisciplinary group of experts. The methodological approach combines systematic review with expert judgement. Recommendations take into account the effectiveness and toxicity of the different therapeutic alternatives and the levels of evidence. Following their development and prior to publication, independent practitioners in cancer care delivery reviewed SOR-guidelines. Therapeutic standards and options concerning adjuvant or neoadjuvant chemotherapy as well as adjuvant radiotherapy have been defined per stage (IA, IB, II and IIIA). Specific chemotherapy regimens have also been recommended. After critical appraisal, the literature data appeared sufficient to update the recommendations validated in 2000. The literature will be searched and reexamined in 2008 within SOR's systematic monitoring.
AB - An update of the Sor Clinical Practice Guidelines (CPG) for the perioperative treatment of operable patients with resecable non-small cell lung cancer, operable has been initiated by the French National Federation of Cancer Centres (FNCLCC). This work was performed in collaboration with the French Intergroup for Thoracic Oncology (IFCT), the French-speaking Language Society of Pneumology (SPLF), specialists from university or general hospitals and private clinics, and with the French National Cancer Institute. It is based on the methodology developed and used in the "Standards, Options and Recommendations" programme. This article presents a short version of the updated 2007 recommendations. The guideline development process is based on literature review and critical appraisal by amultidisciplinary group of experts. The methodological approach combines systematic review with expert judgement. Recommendations take into account the effectiveness and toxicity of the different therapeutic alternatives and the levels of evidence. Following their development and prior to publication, independent practitioners in cancer care delivery reviewed SOR-guidelines. Therapeutic standards and options concerning adjuvant or neoadjuvant chemotherapy as well as adjuvant radiotherapy have been defined per stage (IA, IB, II and IIIA). Specific chemotherapy regimens have also been recommended. After critical appraisal, the literature data appeared sufficient to update the recommendations validated in 2000. The literature will be searched and reexamined in 2008 within SOR's systematic monitoring.
KW - Carcinoma
KW - Chemotherapy adjuvant
KW - Neoadjuvant therapy
KW - Nonsmall-cell lung
KW - Practice guidelines
KW - Radiotherapy adjuvant
UR - http://www.scopus.com/inward/record.url?scp=37049029631&partnerID=8YFLogxK
U2 - 10.1007/s10269-007-0777-z
DO - 10.1007/s10269-007-0777-z
M3 - Article 'review'
AN - SCOPUS:37049029631
SN - 1292-3818
VL - 9
SP - 800
EP - 809
JO - Oncologie
JF - Oncologie
IS - 11
ER -